NCI
Biden Cancer Moonshot Announces New Initiatives to Improve Diagnosis, Precision Treatments
The program announced a series of new public and private initiatives and projects designed to support its stated goal of halving the cancer death rate over the next 25 years.
Aptose Partners With NCI to Study Tuspetinib in MyeloMATCH Trials
NCI will include the multi-kinase inhibitor in the umbrella trial evaluating targeted therapy combinations in AML and MDS patients.
Marengo Therapeutics Advancing Bispecific Antibody to Phase II After Positive First-in-Human Data
Premium
A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.
Caris Life Sciences, ECOG-ACRIN to Analyze Breast Tumor Samples From Landmark TAILORx Study
Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.
National Cancer Institute Launches MyeloMATCH Myeloid Cancer Treatment Clinical Trial
The trial aims to enroll several thousand patients to test precision medicine treatments for bone marrow and blood cancers.